Search results

• 2021

  Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

  Monin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., Del Molino Del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., Abdul-Jawad, S., Kamdar, S., Harvey-Jones, E., Graham, R., Cooper, J., Khan, M., Vidler, J., Kakkassery, H., Sinha, S., Davis, R., & 24 othersDupont, L., Francos Quijorna, I., O'Brien-Gore, C., Lee, P. L., Eum, J., Conde Poole, M., Joseph, M., Davies, D., Wu, Y., Swampillai, A., North, B. V., Montes, A., Harries, M., Rigg, A., Spicer, J., Malim, M. H., Fields, P., Patten, P., Di Rosa, F., Papa, S., Tree, T., Doores, K. J., Hayday, A. C. & Irshad, S., Jun 2021, In: The Lancet Oncology. 22, 6, p. 765-778 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Immunogenicity 100%
  • Observational Study 100%
  • COVID-19 Vaccine 100%
  • COVID-19 100%
  • Severe Acute Respiratory Syndrome Coronavirus 2 30%
  453 Citations (Scopus)